I do not know Fatchoy.
I have seen BP and someone else has circa $2 targets but I have never seen a critical analysis of management (outside of Morgans) or a comprehensive analysis on costs from any research or analyst.
So to be blunt, no-one who is receiving corporate fees from the company has been critical (or accurate) of the management thus far.
To go a step further, who is advising the company on their shareholder base? There is no anchor investor from the healthcare sector, so how is BP earning their dollars, is it just by placing shares in a heavily discounted capital raise??
Maybe they are earning their dollars via the take over defence that keeps being touted!
PAR. SP, page-122
Add PAR (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
22.5¢ |
Change
0.010(4.65%) |
Mkt cap ! $78.73M | |||
| Open | High | Low | Value | Volume |
| 22.0¢ | 23.5¢ | 21.5¢ | $288.5K | 1.279M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 6 | 130626 | 22.5¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 23.0¢ | 60000 | 1 |
View Market Depth
| Last trade - 16.10pm 08/11/2024 (20 minute delay) ? |
| PAR (ASX) Chart |